Muscarinic receptor subtypes in the human colon: Lack of evidence for atypical subtypes

European Journal of Pharmacology

Volumn 482, Issue 1-3, 2003, Pages 101-109

  Mansfield, Kylie J ^a   Mitchelson, Frederick J ^b   Moore, Kate H ^c   Burcher, Elizabeth ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

Alkylating agent; Circular muscle; Colon; Human; Muscarinic receptor; Radioligand binding; 3H Quinuclidinyl benzylate

Indexed keywords

1 (2 CHLOROETHYL) 4 DIPHENYLACETOXYPIPERIDINE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ALKYLATING AGENT; DARIFENACIN; MAMBA TOXIN 1; MAMBA TOXIN 4; METHOCTRAMINE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; PIPERIDINE; PIRENZEPINE; QUINUCLIDINYL BENZILATE; RECEPTOR SUBTYPE; TOXIN; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; FEMALE; HUMAN; KINETICS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGMOID;

EID: 0344737705     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.10.008     Document Type: Article

References (41)

1. Barlow R.B., Shepherd M.K., Veale M.A. Some differential effects of 4-diphenylacetoxy-N-(2-chloroethyl)-piperidine hydrochloride on guinea-pig atria and ileum. J. Pharm. Pharmacol. 42:1990;412-418.
2. Bellido I., Fernandez J.L., Gomez A., Sanchez de la Cuesta F. Otenzepad shows two populations of binding sites in human gastric smooth muscle. Can. J. Physiol. Pharm. 73:1995;124-129.
3. Burcher E., Shang F., Byrne C., King D.W., Liu L. Expression and location of muscarinic receptor subtypes in human colon. Proc. Australas. Soc. Clin. Exp. Pharmacol. Toxicol. 10:2003;. (in press).
4. 4 receptor subtypes using receptor knockout mice. Life Sci. 68:2001;2473-2479.
5. + channels by protein kinase A and phosphatase inhibitors. Am. J. Physiol. 261:1991;C387-C392.
6. Caulfield M.P., Birdsall N.J. International Union of Pharmacology: XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50:1998;279-290.
7. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
8. Christopoulos A., Loiacono R., Mitchelson F. Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3′-phthalimidopropyl) ammonium bromide at cholinoceptor sites. Eur. J. Pharmacol. 246:1993;1-8.
9. 2 muscarinic receptors to ERK MAP kinases and caldesmon phosphorylation in colonic smooth muscle. Am. J. Physiol. 278:2000;G429-G437.
10. De Lean A., Hancock A.A., Lefkowitz R.J. Validation and statistical analysis of a computer modelling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol. Pharmacol. 21:1982;5-16.
11. Dörje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M.R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256:1991;727-733.
12. Eglen R.M. Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci. 68:2001;2573-2578.
13. Eglen R.M., Michel A.D., Montgomery W.W., Kunysz E.A., Machado C.A., Whiting R.L. The interaction of parafluorohexahydrosiladiphenidol at muscarinic receptors in vitro. Br. J. Pharmacol. 99:1990;637-642.
14. Eglen R.M., Reddy H., Watson N., Challiss J. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol. Sci. 15:1994;114-119.
15. Eglen R.M., Hegde S.S., Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol. Rev. 48:1996;531-565.
16. Ehlert F.J., Griffin M.T. The use of irreversible ligands to inactivate receptor subtypes: 4-DAMP mustard and muscarinic receptors in smooth muscle. Life Sci. 62:1998;1659-1664.
17. Ehlert F.J., Oliff H.S., Griffin M.T. The quaternary transformation products of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) have differential affinity for subtypes of the muscarinic receptor. J. Pharmacol. Exp. Ther. 276:1996;405-410.
18. 3 muscarinic receptors in gastrointestinal smooth muscle. Life Sci. 64:1999;387-394.
19. Fang Y.I., Iijima M., Ogawa M., Suzuki T., Momose K. Reduction in the numbers of muscarinic receptors by an endogenous protein. Biochem. Pharmacol. 46:1993;637-641.
20. Gillberg P.G., Sundquist S., Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur. J. Pharmacol. 349:1998;285-292.
21. Gitler M.S., Reba R.C., Cohen V.I., Rzeszotarski W.J., Jin B., Baumgold J. A novel M2-selective muscarinic antagonist: binding characteristics and autoradiographic distribution in rat brain. Brain Res. 582:1992;253-260.
22. Gomez A., Martos F., Bellido I., Marquez E., Garcia A.J., Pavia J., Sanchez de la Cuesta F. Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem. Pharmacol. 43:1992;2413-2419.
23. Kerr P.M., Hillier K., Wallis R.M., Garland C.J. Characterization of muscarinic receptors mediating contractions of circular and longitudinal smooth muscle of human isolated colon. Br. J. Pharmacol. 115:1995;1518-1524.
24. Kunze W.A., Furness J.B. The enteric nervous system and regulation of intestinal motility. Annu. Rev. Physiol. 61:1999;117-142.
25. Lee J.H., el-Fakahany E.E. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates. J. Pharmacol. Exp. Ther. 233:1985;707-714.
26. Mansfield K.J., Mitchelson F.J., Moore K.H., Burcher E. Muscarinic receptor binding in human detrusor - age related changes. Neurourol. Urodyn. 22:2003;527-529.
27. Miller J.H., Aagaard P.J., Gibson V.A., McKinney M. Binding and functional selectivity of himbacine for cloned and neuronal muscarinic receptors. J. Pharmacol. Exp. Ther. 263:1992;663-667.
28. Motulsky H.J., Mahan L.C. The kinetics of competitive ligand binding produced by the law of mass action. Mol. Pharmacol. 25:1984;1-9.
29. Moriya H., Takagi Y., Nakanishi T., Hayashi M., Tani T., Hirotsu I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mACh) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 64:1999;2351-2358.
30. Preiksaitis H.G., Krusiak P.S., Chrones T., Rajgopal V., Laurier L.G. Pharmacological and molecular characterization of muscarinic receptor subtypes in human esophageal smooth muscle. J. Pharmacol. Exp. Ther. 295:2000;879-888.
31. 3 muscarinic receptors in the guinea pig colon. J. Pharmacol. Exp. Ther. 284:1998;269-277.
32. 4 receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J. Pharmacol. Exp. Ther. 292:2000;877-885.
33. Thomas E.A., Hsu H.H., Griffin M.T., Hunter A.L., Luong T., Ehlert F.J. Conversion of N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) to an aziridinium ion and its interaction with muscarinic receptors in various tissues. Mol. Pharmacol. 41:1992;718-726.
34. Waelbroeck M., Renzetti A.R., Tastenoy M., Barlow R.B., Christophe J. Inactivation of brain cortex muscarinic receptors by 4-diphenylacetoxy-1-(2- chloroethyl) piperidine mustard. Biochem. Pharmacol. 44:1992;285-290.
35. 3 receptor antagonists. Life Sci. 56:1995;861-868.
36. Wallis R.M., Napier C.M. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci. 64:1999;395-401.
37. 5 muscarinic receptors expressed in CHO-K1 cells. Br. J. Pharmacol. 127:1999;590-596.
38. Wess J., Lambrecht G., Mutschler E., Brann M.R., Dörje F. Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations. Br. J. Pharmacol. 102:1991;246-250.
39. Zhang L.B. Muscarinic receptors in developing rat colon. Eur. J. Pharmacol. 304:1996;211-219.
40. Zholos A.V., Bolton T.B. Effects of divalent cations on muscarinic receptor cationic current in smooth muscle from guinea-pig small intestine. J. Physiol. 486:1995;67-82.
41. 3 subtypes. Mol. Pharmacol. 40:1991;943-951.